<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium iodide (SSKI, Thyroshield): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium iodide (SSKI, Thyroshield): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium iodide (SSKI, Thyroshield): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11439" href="/d/html/11439.html" rel="external">see "Potassium iodide (SSKI, Thyroshield): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12718" href="/d/html/12718.html" rel="external">see "Potassium iodide (SSKI, Thyroshield): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F211985"><span class="drugH1">Brand Names: US</span>
<ul>
<li>iOSAT [OTC];</li>
<li>SSKI;</li>
<li>ThyroSafe [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F212014"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Antithyroid Agent;</li>
<li>
                        Expectorant</li></ul></div>
<div class="block doa drugH1Div" id="F211987"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses may be presented as drops, mL, or mg depending on indication and/or product. SSKI solution contains potassium iodide 1 g per mL; 1 drop = 0.05 mL = 50 mg (ATA [Ross 2016]). Errors have occurred involving iodine-containing solutions; verify the indication and intended solution concentration before administration (ISMP 2011).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ed29208-35c6-4bd2-aadd-4dfcb1629073">Expectorant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Expectorant:</b>
<b>Oral:</b> SSKI solution: 300 to 600 <b>mg</b> (0.3 to 0.6 mL) 3 to 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b71d9a92-75e1-4e23-b84e-4361a1e98524">Graves disease, thyroidectomy preparation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graves disease, thyroidectomy preparation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use is <b>not</b> recommended in patients with thyrotoxicosis caused by a toxic adenoma or toxic multinodular goiter due to the risk of exacerbating hyperthyroidism (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> SSKI solution: 1 to 2 <b>drops</b> (50 to 100 mg <b>or</b> 0.05 to 0.1 mL) 3 times daily for 7 to 10 days before surgery; alternatively, may administer as a single daily dose (ATA [Ross 2016]; Whalen 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antithyroid drug therapy (eg, methimazole) is started several weeks before surgery to achieve euthyroidism; if not euthyroid prior to surgery, or if urgent surgery is required, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (ATA [Ross 2016]; Burch 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a56e3638-2ca2-4065-9aa7-8d2c889e570f">Sporotrichosis, cutaneous or lymphocutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis, cutaneous or lymphocutaneous (alternative agent) (off-label use):</b>
<b>Oral:</b> SSKI solution: Initial: 5 <b>drops</b> (250 mg <b>or </b>0.25 mL) 3 times daily. Increase dose by 3 to 5 <b>drops</b>/day (150 to 250 mg/day <b>or </b>0.15 to 0.25 mL/day) based on response as tolerated up to 50 <b>drops </b>(2.5 g <b>or </b>2.5 mL) 3 times daily; continue therapy until 2 to 4 weeks after lesions have resolved (usual duration: 3 to 6 months) (Kauffman 2007; Rezende 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="592025be-528d-4d1f-9f73-7335bd76c0a9">Thyroid block following nuclear radiation emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid block following nuclear radiation emergency: Includes pregnant or lactating patients:</b>
<b>Oral:</b> iOSAT or ThyroSafe: 130 mg once daily; continue for 10 to 14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For internal exposure to radioactive iodine, patients should receive potassium iodide following known or predicted thyroid exposures as follows (AAP 2003; AAP [Linet 2018]; REMM 2022a; REMM 2022b):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>&gt;40 years of age:</i> ≥5 Gy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>18 to 40 years of age:</i> ≥0.1 Gy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pregnant or lactating patients:</i> ≥0.05 Gy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="983b48df-1521-45eb-aacb-baab001e0e41">Thyroid gland protection during radiopharmaceutical use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid gland protection during radiopharmaceutical use (off-label use):</b>
<b>Oral:</b> Tablets or SSKI solution: 130 to 300 <b>mg</b> (~3 to 6 drops <b>or </b>~0.15 to 0.3 mL SSKI solution) per day (ACR-ACNM [Subramaniam 2017]; ACR-SPR 2015; Bombardier 2010; Taïeb 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Begin at 1 to 48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer at least 1 hour after antithyroid drug administration (eg, propylthiouracil, methimazole) (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> SSKI solution: 5 <b>drops</b> (250 mg <b>or</b> 0.25 mL) every 6 hours (ATA [Ross 2016]). May discontinue after evidence of clinical improvement (eg, defervescence, resolution of CNS and cardiovascular manifestations); for patients undergoing thyroidectomy within 10 to 14 days of initiating iodine therapy, may continue until day of surgery (ATA [Ross 2016]; Nayak 2006; Ross 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992007"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50989249"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F211988"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F212001"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12718" href="/d/html/12718.html" rel="external">see "Potassium iodide (SSKI, Thyroshield): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses may be presented as drops, mL, or mg depending on indication and/or product. SSKI contains 1 g/mL; 1 drop = 0.05 mL = 50 mg (ATA [Ross 2016]). Use caution to ensure the proper dose is ordered and administered.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eac9d14b-b07c-46a7-8d7f-4004fa113e08">Sporotrichosis, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis, cutaneous:</b>
<b>Note: </b>Alternative agent: Limited data available: Children and Adolescents: <b>SSKI 1 g/mL:</b> Oral: Initial: 1 <b>drop</b> (50 mg or 0.05 mL) 3 times daily; increase dose as tolerated; maximum dose: 1 <b>drop</b>/kg/dose <b>or </b>50 <b>drops</b>/dose, whichever is lowest; continue at the maximum tolerated dosage for several weeks after lesions have resolved (IDSA [Kauffman 2007]; <i>Red Book</i> [AAP 2018]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="592025be-528d-4d1f-9f73-7335bd76c0a9">Thyroid block following nuclear radiation emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid block following nuclear radiation emergency:</b>
<b>Iosat, ThyroSafe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Continue treatment for 10 to 14 days or as directed by public officials (until the risk of exposure has passed or other measures are implemented) (FDA 2001). For internal exposure to radioactive iodine, pediatric patients should receive potassium iodide following known or predicted thyroid exposures ≥0.05 Gy (AAP 2003; AAP [Linet 2018]; REMM 2022c).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤3 years: Oral: 32.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;3 to 12 years: Oral: 65 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;68 kg: Oral: 65 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥68 kg: Oral: 130 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="983b48df-1521-45eb-aacb-baab001e0e41">Thyroid gland protection during radiopharmaceutical use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid gland protection during radiopharmaceutical use:</b> Limited data available; <b>Note:</b> Begin at 1 to 48 hours prior to exposure; continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical; consult specific protocol):</p>
<p style="text-indent:-2em;margin-left:4em;">Age-directed dosing (Olivier 2003):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;3 years: Oral: 32 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents 3 to 13 years: Oral: 65 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;13 years: Oral: 130 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing (Giammarile 2008):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;5 kg: Oral: 16 mg once daily.</p>
<p style="text-indent:-4em;margin-left:8em;">5 to &lt;15 kg: Oral: 32 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;50 kg: Oral: 65 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: Oral: 130 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3592258d-f581-413a-a562-24bb4c449577">Thyroidectomy in Graves disease, preoperative preparation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroidectomy in Graves disease, preoperative preparation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving methimazole: </i>Children and Adolescents: <b>SSKI 1 g/mL:</b> Oral: 1 to 2 <b>drops</b> (50 to 100 mg or 0.05 to 0.1 mL) 3 times daily; administer for 10 days prior to surgery (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients unable to take or intolerant to methimazole or need for urgent thyroidectomy: </i>Children and Adolescents: <b>SSKI 1 g/mL:</b> Oral: 3 to 7 <b>drops</b> (150 to 350 mg or 0.15 to 0.35 mL) 3 times daily; administer for 10 days before surgery in combination with beta-blockade (ATA [Ross 2016]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="576f3ec3-d7e5-4014-894e-a3b2f651e2bc">Thyrotoxic crisis/thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxic crisis/thyroid storm:</b> (Eyal 2008): <b>Note:</b> Administer at least 1 hour after antithyroid drug (eg, methimazole) administration:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: <b>SSKI 1 g/mL:</b> Oral: 2 <b>drops</b> (100 mg or 0.1 mL) 4 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: <b>SSKI 1 g/mL:</b> Oral: 5 <b>drops</b> (250 mg or 0.25 mL) 2 to 4 times daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154211"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51154212"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F211954"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmias</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea, gastric distress, gastrointestinal hemorrhage, nausea, sialadenitis (including tenderness), stomach pain, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Nervous system: Asthenia (hands and feet), confusion, fatigue, numbness, tingling sensation</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Lower extremity pain (feet), upper extremity pain (hands)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pharyngeal edema</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever, neck edema</p></div>
<div class="block coi drugH1Div" id="F211969"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to iodide, iodine, or any component of the formulation; dermatitis herpetiformis; hypocomplementemic vasculitis, nodular thyroid condition with heart disease</p></div>
<div class="block war drugH1Div" id="F211951"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Iodide hypersensitivity may occur, manifesting as angioedema, cutaneous/mucosal hemorrhage, and serum sickness-like symptoms (fever, arthralgia, lymph node enlargement, and eosinophilia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Can cause acne flare-ups and/or dermatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid adverse effects: Prolonged use may lead to hypothyroidism. Iodide may cause underactive or overactive thyroid; thyroid enlargement may also occur. Use with caution in patients with a history of hyperthyroidism. Iodism or chronic iodide poisoning may occur with high doses or prolonged treatment; symptoms include burning of mouth/throat, sore teeth/gums, severe headache, metallic taste, eye irritation/eye lid swelling, increased salivation, acneform skin lesions, and (rarely) severe skin lesions; withhold potassium iodide treatment and manage with supportive care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with Addison disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchitis: Use with caution in patients with acute bronchitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Use with caution in patients with cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myotonia congenita: Use with caution in patients with myotonia congenita.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: Use with caution in patients with tuberculosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: In a nuclear radiation emergency, infants and children are more likely to experience thyroid damage. Neonates &lt;1 month are at higher risk for hypothyroidism with potassium iodide use; evaluate thyroid function if repeat dosing is required in this patient population.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For thyroid gland protection (radiopharmaceutical use), potassium iodide must be administered prior to receiving radiopharmaceuticals that require thyroid gland protection. For nuclear radiation emergency, take only when instructed by public health officials; do not take more or more often than instructed; follow other emergency measures recommended by officials.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878598"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution in patients with cystic fibrosis; may have exaggerated susceptibility to goitrogenic effects (Dolan 1971).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F211963"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">SSKI: 1 g/mL (30 mL, 237 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 65 mg/mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">iOSAT: 130 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;">ThyroSafe: 65 mg [scored]</p></div>
<div class="block geq drugH1Div" id="F13755335"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F211972"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Iodide (Antidote) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">65 mg/mL (per mL): $0.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (SSKI Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/mL (per mL): $17.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F211965"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">SSKI solution: Dilute in a glassful of water, fruit juice, or milk. Administer with food or milk to decrease gastric irritation. In patients with thyroid storm, administer at least 1 hour after antithyroid drug administration (eg, propylthiouracil, methimazole).</p>
<p style="text-indent:-2em;margin-left:2em;">iOSAT, ThyroSafe: Administer as soon as possible after instructed to do so by public officials. Do not take more than 1 dose in 24 hours. Tablets may be administered whole or crushed and then mixed with water, low fat milk (white or chocolate), orange juice, soda (flat), raspberry syrup, or infant formula. Raspberry syrup disguises the taste best; low-fat white milk or water do not hide the salty taste well) (AAP 2003). See Extemporaneously Prepared.</p></div>
<div class="block admp drugH1Div" id="F52613634"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">SSKI: Dilute with a large quantity of water, fruit juice, milk, or broth; take with food or milk to decrease gastric irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">Iosat, ThyroSafe: Take as soon as possible after instructed to do so by public officials. Take every 24 hours; do not take more than 1 dose in 24 hours. Tablets may be crushed and mixed with water, low fat milk (white or chocolate), orange juice, soda (flat), raspberry syrup, or infant formula. Raspberry syrup disguises the taste best; low-fat white milk or water do not hide the salty taste well (AAP 2003).</p></div>
<div class="block use drugH1Div" id="F211964"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid block following nuclear radiation emergency:</b> Block thyroidal uptake of radioactive isotopes of iodine in a nuclear radiation emergency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Expectorant:</b> Expectorant for the symptomatic treatment of chronic pulmonary diseases complicated by mucous.</p></div>
<div class="block off-label drugH1Div" id="F25471004"><span class="drugH1">Use: Off-Label: Adult</span><p>Graves disease, thyroidectomy preparation; Sporotrichosis, cutaneous or lymphocutaneous (alternative); Thyroid gland protection during radiopharmaceutical use; Thyroid storm</p></div>
<div class="block mst drugH1Div" id="F802361"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Potassium iodide products, including saturated solution of potassium iodide (SSKI) may be confused with potassium iodide and iodine (Strong Iodide Solution or Lugol's solution)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dosage volume: Dosing errors have been reported during the prescribing, dispensing, and administration of potassium iodide-containing solutions (eg, Lugol's, SSKI). Errors have occurred when <b>mL</b> doses were administered, when only <b>drops</b> were indicated for the dose. Carefully review dosage and administration information; appropriate oral dosage is most commonly expressed as drops to provide doses less than 1 mL. Dispensing unit doses is also highly recommended; pharmacists should never dispense quantities that could be lethal if consumed as a single dose. (ISMP 2011).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299922"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211956"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antithyroid Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antithyroid agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Potassium Iodide may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue potassium iodide at least 3 weeks before sodium iodide I-131 administration, and avoid concurrent use.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F211973"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Potassium iodide is approved for use during a nuclear radiation emergency to block thyroidal uptake of radioactive isotopes of iodine. During an emergency, pregnant patients are at a high risk of developing thyroid dysfunction and thyroid cancer following exposure and should be prioritized for potassium iodide treatment. Treatment should begin immediately before or during the passage of the radioactive cloud, but delayed administration is still beneficial. Repeated doses may suppress fetal thyroid function and are therefore not recommended. Instead, pregnant patients should be prioritized for evacuation from the exposure area (AAP [Linet 2018]; ATA [Leung 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">If inadvertent exposure to the therapeutic use of sodium iodide I<sup>131</sup> during pregnancy occurs, maternal potassium iodide may be administered to protect the fetal thyroid. Treatment must be given within 12 hours of exposure but may not be needed if the mother is &lt;12 weeks gestation (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Potassium iodide may also be used off label in patients with Graves disease undergoing thyroidectomy. Potassium iodide is recommended for use in pregnant patients with hyperthyroidism who do not tolerate antithyroid medications in preparation for surgery (ATA [Alexander 2017]). Potassium iodide may also be used in the management of thyroid storm or thyrotoxic heart failure in pregnant patients (ACOG 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Use of potassium iodide as an expectorant is not recommended in pregnant patients. Neonatal hypothyroidism and goiter (in some cases causing tracheal obstruction leading to neonatal death) have been reported following chronic maternal use as an expectorant (AAP 1976; Bostanci 2001).</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to Sodium Iodide monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F211974"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Potassium iodide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Exposure to potassium iodide via breast milk may cause skin rash and thyroid suppression in the breastfed infant.</p>
<p style="text-indent:-2em;margin-left:2em;">Potassium iodide is approved for use during a nuclear radiation emergency to block thyroidal uptake of radioactive isotopes of iodine. In this scenario, exposure to iodide I<sup>131</sup> via breast milk is expected to be higher than potassium iodide treatment ingested by the mother. During an emergency, breastfeeding patients are at a high risk of developing thyroid dysfunction and thyroid cancer following exposure and should be prioritized for potassium iodide treatment. Treatment should begin immediately before or during the passage of the radioactive cloud, but delayed administration is still beneficial. Repeated doses of potassium iodide are not recommended. Instead, breastfeeding patients should be prioritized for evacuation from the exposure area. Breast milk can be expressed and discarded until it is deemed safe to resume feeding (AAP [Linet 2018]; ATA [Leung 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended when potassium iodide is used as an expectorant (AAP 1976).</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to Sodium Iodide monograph for additional information.</p></div>
<div class="block mop drugH1Div" id="F211961"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Thyroid function tests (thyroid function should be monitored in patients who are pregnant or lactating, neonates, and young infants if repeat doses are required following radioactive iodine exposure); signs/symptoms of hypo- or hyperthyroidism.</p></div>
<div class="block pha drugH1Div" id="F211950"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reduces viscosity of mucus by increasing respiratory tract secretions; inhibits secretion of thyroid hormone, fosters colloid accumulation in thyroid follicles. Following radioactive iodine exposure, potassium iodide blocks the uptake of radioactive iodine by the thyroid, reducing the risk of thyroid cancer. </p></div>
<div class="block phk drugH1Div" id="F211968"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hyperthyroidism: 24 to 48 hours (Nayak 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Hyperthyroidism: ~2 weeks after continuous therapy (Nayak 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Radioactive iodine exposure: Each dose has a duration of ~24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038775"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Jodid | Kaliumjodid lannacher</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Herbs of gold iodine max</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Antistrumin | Iodastrumin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Iodesin | Iodeto de potassio</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Yodafar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kalium iodide</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alpha jod | Jod beta | Jodetten | Jodgamma | Jodid | Jodid hexal | Jodinat | Kalium jodatum | Kaliumjodid | Thyprotect</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Antistrumin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Thyrosafe</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ioduro potasico | Yodafar | Yoduk</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Iodure de potassium</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Iodine | Thysat</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Jodomax | KALIUM-JODID-EP</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Jodetten</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Huons potassium iodide | Thiodan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Thyrosafe</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Yodafar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Jodas vitamir | Kaliumjodide g.l. | Potassium iodide g.l. pharma</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kaliumiodid bc</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Jodix | Kaliumiodid lannacher | Kaliumjodid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aft Neurotabs | Iosat</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Jodid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sski | Thyrosafe | Yodefan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Yodafar | Yodiquer</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Iodura de potasiu atb | Jodid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Antistrumin | Iodandin | Iodin | Iodine vitrum | Iodomarin | Kalium iodidum | Kalium iodidum reneval | Microiodid 100 | Microiodid 200</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kaliumjodid recip | Kaliumjodid rph pharma</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Jodid | Jodid draselny g.l pharma</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Jodid | Rich vital iodine booster</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Iodine Normil | Iodomarin | Jodid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ACRSPR.1">
<a name="ACRSPR.1"></a>ACR-SPR Practice parameter for the performance of tumor scintigraphy (with gamma cameras). https://www.acr.org/-/media/ACR/Files/Practice-Parameters/tumorscint.pdf?la=en. Revised 2015. Accessed May 14, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. <i>Thyroid</i>. 2017;27(3):315-389. doi:10.1089/thy.2016.0457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1250663">
<a name="1250663"></a>American Academy of Pediatrics (AAP), Committee on Drugs. Adverse reactions to iodide therapy of asthma and other pulmonary diseases. <i>Pediatrics</i>. 1976;57(2):272-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/1250663/pubmed" id="1250663" target="_blank">1250663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12777572">
<a name="12777572"></a>American Academy of Pediatrics Committee on Environmental Health. Radiation disasters and children. <i>Pediatrics.</i> 2003;111(6, pt 1):1455-1466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/12777572/pubmed" id="12777572" target="_blank">12777572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443080">
<a name="32443080"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 223: Thyroid disease in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/32443080/pubmed" id="32443080" target="_blank">32443080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bexxar.1">
<a name="Bexxar.1"></a>Bexxar (tositumomab and iodine I 131 tositumomab) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20644928">
<a name="20644928"></a>Bombardieri E, Giammarile F, Aktolun C, et al; European Association for Nuclear Medicine. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. <i>Eur J Nucl Med Mol Imaging</i>. 2010;37(12):2436-2446. doi:10.1007/s00259-010-1545-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/20644928/pubmed" id="20644928" target="_blank">20644928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11592576">
<a name="11592576"></a>Bostanci I, Sarioģlu A, Ergin H, Akşit A, Cinbiş M, Akalin N. Neonatal goiter caused by expectorant usage. <i>J Pediatr Endocrinol Metab</i>. 2001;14(8):1161-1162. doi:10.1515/jpem-2001-0815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/11592576/pubmed" id="11592576" target="_blank">11592576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26670972">
<a name="26670972"></a>Burch HB, Cooper DS. Management of Graves disease: a review. <i>JAMA</i>. 2015;314(23):2544-2554. doi:10.1001/jama.2015.16535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/26670972/pubmed" id="26670972" target="_blank">26670972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5094264">
<a name="5094264"></a>Dolan TF Jr, Gibson LE. Complications of iodide therapy in patients with cystic fibrosis. <i>J Pediatr</i>. 1971;79(4):684-687.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/5094264/pubmed" id="5094264" target="_blank">5094264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eyal.2008">
<a name="Eyal.2008"></a>Eyal O, Rose SR. Thyroid Disease. In: David G Nichols, ed. <i>Roger’s Textbook of Pediatric Intensive Care.</i> 4th ed. Lippincott, Williams, &amp; Wilkins; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Guidance: potassium iodide as a thyroid blocking agent in radiation emergencies. <a href="https://www.fda.gov/media/72510/download" target="_blank">https://www.fda.gov/media/72510/download</a>. Published December 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18274745">
<a name="18274745"></a>Giammarile F, Chiti A, Lassmann M, et al. EANM Procedure Guidelines for 131 I-meta-iodobenzylguanidine (131 I-mIBG) Therapy. <i>Eur J Nucl Med Mol Imaging.</i> 2008;35(5):1039-1047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/18274745/pubmed" id="18274745" target="_blank">18274745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). Look out for Lugol’s...Error-prevention strategies for this strong iodine solution. ISMP Medication Safety Alert, December 1, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Iosat.1">
<a name="Iosat.1"></a>Iosat (potassium iodide tablets) [prescribing information]. Williamsburg, VA: Anbex Inc; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968818">
<a name="17968818"></a>Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2007;45(10):1255-1265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/17968818/pubmed" id="17968818" target="_blank">17968818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28537500">
<a name="28537500"></a>Leung AM, Bauer AJ, Benvenga S, et al. American Thyroid Association scientific statement on the use of potassium iodide ingestion in a nuclear emergency. <i>Thyroid</i>. 2017;27(7):865-877. doi:10.1089/thy.2017.0054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/28537500/pubmed" id="28537500" target="_blank">28537500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30478243">
<a name="30478243"></a>Linet MS, Kazzi Z, Paulson JA; Council on Environmental Health. Pediatric considerations before, during, and after radiological or nuclear emergencies. <i>Pediatrics</i>. 2018;142(6):e20183001. doi:10.1542/peds.2018-3001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/30478243/pubmed" id="30478243" target="_blank">30478243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127140">
<a name="17127140"></a>Nayak B, Burman K. Thyrotoxicosis and Thyroid Storm. <i>Endocrinol Metab Clin North Am.</i> 2006,35(4):663-686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/17127140/pubmed" id="17127140" target="_blank">17127140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12658506">
<a name="12658506"></a>Olivier P, Colarinha P, Fettich J, et al. Guideline for Radioiodinated MIBG Scintigraphy in Children. <i>Eur J Nucl Med Mol Imaging.</i> 2003;30(5):B45-B50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/12658506/pubmed" id="12658506" target="_blank">12658506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mission.1">
<a name="Mission.1"></a>Potassium iodide solution [prescribing information]. San Antonio, TX: Mission Pharmacal Company; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34909873">
<a name="34909873"></a>Rezende HD, Madia ACT, Mateus AD, et al. Itraconazole versus potassium iodide for cutaneous sporotrichosis: weighing up the pros and cons. <i>Rev Assoc Med Bras (1992)</i>. 2021;67(11):1529-1530. doi:10.1590/1806-9282.20210694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/34909873/pubmed" id="34909873" target="_blank">34909873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Thyroid storm. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6688081">
<a name="6688081"></a>Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. <i>J Clin Endocrinol Metab</i>. 1983;57(2):250-253. doi:10.1210/jcem-57-2-250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/6688081/pubmed" id="6688081" target="_blank">6688081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25178068">
<a name="25178068"></a>Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg + inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. <i>Thyroid</i>. 2015;25(1):43-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/25178068/pubmed" id="25178068" target="_blank">25178068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SSKI.1">
<a name="SSKI.1"></a>SSKI (potassium iodide) [prescribing information]. Maple Grove, MN: Upsher-Smith; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28922189">
<a name="28922189"></a>Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM practice parameter for the performance of dopamine transporter (DaT) single photon emission computed tomography (SPECT) imaging for movement disorders. <i>Clin Nucl Med</i>. 2017;42(11):847-852. doi:10.1097/RLU.0000000000001815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/28922189/pubmed" id="28922189" target="_blank">28922189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926712">
<a name="22926712"></a>Taïeb D, Timmers HJ, Hindié E, et al; European Association of Nuclear Medicine. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>Eur J Nucl Med Mol Imaging</i>. 2012;39(12):1977-1995. doi:10.1007/s00259-012-2215-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/22926712/pubmed" id="22926712" target="_blank">22926712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ThyroSafe.1">
<a name="ThyroSafe.1"></a>ThyroSafe (potassium iodide) [prescribing information]. Honey Brook, PA: Recipharm Inc; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REMM.3">
<a name="REMM.3"></a>US Department of Health and Human Services, Radiation Emergency Medical Management (REMM). Isotopes of interest: properties, treatment, and fact sheets. <a href="https://remm.hhs.gov/isotopestable.pdf" target="_blank">https://remm.hhs.gov/isotopestable.pdf</a>. Accessed February 2, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REMM.2">
<a name="REMM.2"></a>US Department of Health and Human Services. Radiation Emergency Medical Management (REMM). Potassium iodide. <a href="https://www.remm.hhs.gov/potassiumiodide.htm" target="_blank">https://www.remm.hhs.gov/potassiumiodide.htm</a>. Updated February 17, 2022. Accessed February 22, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REMM.1">
<a name="REMM.1"></a>US Department of Health and Human Services. Radiation Emergency Medical Management (REMM). Radiation countermeasures for treatment of internal contamination. <a href="https://www.remm.hhs.gov/Countermeasures.pdf" target="_blank">https://www.remm.hhs.gov/Countermeasures.pdf</a>. Accessed February 22, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA's guidance on protection of children and adults against thyroid cancer in case of nuclear accident. FDA Talk Paper; issued December 2001. <a href="http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133711.htm" target="_blank">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133711.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27769543">
<a name="27769543"></a>Whalen G, Sullivan M, Maranda L, Quinlan R, Larkin A. Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves' disease. <i>Am J Surg</i>. 2017;213(4):805-809. doi:10.1016/j.amjsurg.2016.07.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/27769543/pubmed" id="27769543" target="_blank">27769543</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9798 Version 178.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
